Literature DB >> 18325314

Heparin-induced thrombocytopenia: 2008 update.

John R Bartholomew1.   

Abstract

Unfractionated heparin (UFH) and the low molecular weight heparin (LMWH) preparations are two of the most commonly prescribed medications in the hospital, and indications for their use are increasing. An increasingly recognized untoward effect of either UFH or LMWH is heparin-induced thrombocytopenia (HIT), a transient, prothrombotic condition that may result in venous or arterial thrombosis and amputation or death. This immune-mediated process generally develops within 4 to 14 days of administration, although it may occur more rapidly if there has been a recent exposure; it may even occur days to weeks after UFH or LMWH has been discontinued. Although once considered necessary for the diagnosis of HIT, thrombocytopenia is no longer essential. A 50% reduction in the platelet count from pre-heparin treatment levels is now considered a more specific finding. Prompt recognition, discontinuation of the offending agent, and initiation of an alternative anticoagulant are essential for prevention and/or treatment of these potentially devastating complications.

Entities:  

Year:  2008        PMID: 18325314     DOI: 10.1007/s11936-008-0013-1

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  45 in total

1.  Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia.

Authors:  Jayson C Liu; Bruce E Lewis; Lowell H Steen; Eric D Grassman; Mamdouh Bakhos; Bradford Blakeman; Laura Wrona; Ferdinand Leya
Journal:  Am J Cardiol       Date:  2002-04-15       Impact factor: 2.778

Review 2.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

3.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

4.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

5.  Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.

Authors:  N Lubenow; P Eichler; T Lietz; A Greinacher
Journal:  J Thromb Haemost       Date:  2005-11       Impact factor: 5.824

Review 6.  Testing for heparin-induced thrombocytopenia antibodies.

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard
Journal:  Transfus Med Rev       Date:  2006-10

7.  Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.

Authors:  X Song; G Huhle; L Wang; U Hoffmann; J Harenberg
Journal:  Circulation       Date:  1999-10-05       Impact factor: 29.690

8.  Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

Authors:  Bruce E Lewis; Diane E Wallis; Fred Leya; Marcie J Hursting; John G Kelton
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

Review 9.  Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.

Authors:  Douglas B Cines; Lubica Rauova; Gowthami Arepally; Michael P Reilly; Steven E McKenzie; Bruce S Sachais; Mortimer Poncz
Journal:  J Clin Apher       Date:  2007-02       Impact factor: 2.821

10.  Treatment of heparin-induced thrombocytopenia: a critical review.

Authors:  Jack Hirsh; Nancy Heddle; John G Kelton
Journal:  Arch Intern Med       Date:  2004-02-23
View more
  1 in total

1.  Adding chemoprophylaxis to sequential compression might not reduce risk of venous thromboembolism in bariatric surgery patients.

Authors:  Michel Gagner; Faith Selzer; Steve H Belle; Marc Bessler; Anita P Courcoulas; Gregory F Dakin; Dan Davis; William B Inabnet; James E Mitchell; Alfons Pomp; Gladys W Strain; Walter J Pories; Bruce M Wolfe
Journal:  Surg Obes Relat Dis       Date:  2012-07-31       Impact factor: 4.734

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.